Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
The move – which comes after an agreement by UCB to reduce the price of the drug – makes Evenity (romosozumab) the first novel therapy for the bone-wasting condition to be available to the NHS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results